Two near-term data catalysts expected in 2023
Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and commercialization of NRX-101 in suicidal. -Today at 04:10 pm- MarketScreener
Two near-term data catalysts expected in 2023 Entered active collaboration with Alvogen Pharmaceuticals and Lotus Pharmaceuticals for global development and.
First investigational drug for patients with Severe Bipolar Depression and Acute Suicidal Ideation/Behavior, a high unmet medical need Company received.
Search jobs 19-Feb-2021 Anti-Suicide Drugs Market to Exhibit a Rise by 4.1% CAGR Between 2019 to 2027 | Coherent Market Insights
The
Global
Anti-Suicide Drugs Market, by Drug Class (Anti-Depressant and Anti-Anxiety Drugs, Anti-Psychotic Drugs, NMDA Antagonist, and Antibiotic Analog) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa), was valued at
US$ 3,818.1 million in 2018 and is projected to expand at a
CAGR of 4.1% during the forecast period (2019–2027).
Novel approved drugs, which are expected to be commercialized post-2020, introduced for the treatment of suicidal ideation is expected to drive the global anti-suicide drugs market growth. Until recently, suicidal ideation has been treated with anti-depressants, anti-anxiety, and anti-psychotic drugs. The trend is expected to continue till the expected launch of Cyclurad by NeruoRx Pharma during the latter half of the forecas